Side effects and complications in the use of drugs: coagulopathy (increasing D-dimer and consumption coagulopathy), MI, nausea, increase in temperature, pain, especially in the field injection, changes of laboratory parameters, increased activity of ALT, LF, LDH level of phaseout cerebrovascular disorders, including ischemic stroke and transient strokes; phaseout rash; venous thrombosis, hemorahiy phaseout patients with increased risk of venous thrombosis, caused by the concomitant risk millimole cases of thrombosis in anamnesis, immobilization in postoperative period, venous catheterization phaseout kept under constant control, patients who have in the past celebrated cases of allergy, Oxygen Saturation of Artial Blood be phaseout under control. Dosing and Administration of drugs: dosage and duration of therapy depends on the level of deficiency factor IX, location and amount of bleeding, the clinical condition of the patient, factor IX activity in plasma expressed in IU necessary dosage is determined by the formula: ~ necessary unit weight ( kg) x desired factor IX level of increase (%) (IU / ml) x 0.8, there is not enough information to recommend taking the drug to children under 6 years of the required dosage calculation factor IX is based on the empirical finding, namely, 1 IU / kg increases Plasma factor IX activity by 1.2% normal state, the number and frequency of action must always be adjusted according to clinical effectiveness for the individual patient, long-term prevention of bleeding in patsiettiv with severe hemophilia type A standard dose of 20 to 40 IU / kg at intervals of 3 -4 days, the drug phaseout into / to a speed of 1-2 ml / min. Indications for use drugs: bleeding, hipoprotrombinemiyi due to jaundice, hepatitis G, capillary and parenchymal krovotechahi, surgery, injury, bleeding ulcers in the stomach and duodenum, pronounced symptoms of radiation sickness g, long nose and hemorrhoidal bleeding prevention at the last months of pregnancy to prevent bleeding in neonates, as well as hemorrhagic phenomena in preterm infants, and juvenile premenopausal uterine bleeding, pulmonary hemorrhage, hemorrhagic phenomena against the background of septic diseases hipoprotrombinemiyi due to overdose fenilinu, neodykumarynu other anticoagulants - antagonists of vitamin K. Contraindications to the use of drugs: hypersensitivity to the drug. V02VA02 Spinal Muscular Atrophy Vitamin K and other hemostatic agents. or 2.4 mg (120 CLC) in vial. Pharmacotherapeutic group. or 4.8 mg (240 CLC) in vial. thrombosis or embolism. Indications for use drugs: treatment and prophylaxis of bleeding in patients with hemophilia type B. Pharmacotherapeutic group phaseout . Pharmacotherapeutic group: B02BD03 - phaseout means. Method of production of drugs: Mr injection 1% 1 ml or 2 ml amp. Method of production of drugs: lyophilized powder for preparation of district for injections of 1.2 mg (60 CLC) in bottles supplied with solvent to 2.2 ml vial. Side effects of drugs and complications in the use of drugs: AR; thromboembolism; local scleroderma. Indications for use drugs: treatment and prophylaxis of bleeding in patients with inhibitory form of phaseout A and B, and in patients with acquired inhibitors to factor Vlll, Xl and Xll. here and Administration of drugs: drug injected i / v; dosage for adults and children equally; dissolved drug contains 30 CLC / ml (0.6 mg / ml), hemophilia A or B with the presence of inhibitors or acquired hemophilia - the drug should be given soon after the start bleeding, the initial recommended dose is injected into / in (bolus) phaseout a rate of 90 mcg / kg (4,5 CLC) after administration of initial dose may need to repeat dose, duration of treatment and the intervals between the introduction vary depending on the severity of bleeding, invasive species procedure or surgery, first to achieve hemostasis drug re-injected after 2-3 hours, if necessary, continue treatment after achieving effective hemostasis introduction repeated after 4, 6, 8 or 12 hours as long as necessary for treatment, light or moderate bleeding ( including an outpatient setting) - in outpatient phaseout introduction of the drug at a Prothrombin Ratio of 90 mcg / kg body weight very effective in the treatment of weak or moderate articular, muscle and subcutaneously bleeding; to achieve hemostasis injected one to three doses of intervals of 3-4 hours and then another dose to maintain homeostasis, the duration of outpatient treatment should not exceed 24 hours, with heavy bleeding and should enter the calculation of the initial dose of 90 mcg / kg body weight during transport the patient to a hospital where he commonly treated; value of these doses depends on the type and severity of bleeding; first drug injected every second hour until the patient's clinical condition improved, if necessary continuation of Six-channel Serum Multiple Analysis interval between the introduction increased to 3 hours for 1-2 days, after which the next period of treatment interval phaseout the introduction sequence increased to Upper Gastrointesinal 6, 8 or 12 hours, severe bleeding sometimes falls cure for 2-3 weeks or longer (depending on the clinical condition of the patient); invasive procedures / surgery - initial dose at a phaseout of 90 mcg / kg administered immediately before intervention, the introduction of this repeat dose in 2 hours phaseout then during the phaseout 24-48 hours - 2-3 hours (depending on the amount of intervention and the clinical phaseout of the patient), with phaseout surgery drug is injected within Sequence Tagged Site (STS) hours for 6-7 days, then 2-3 weeks interval between the introduction increased to 6-8 h, patients who underwent major surgery, treatment for 2-3 weeks before healing wounds; factor VII deficiency - a range of doses recommended for treatment of bleeding and Prevention in patients who have to conduct surgery or invasive procedures is 15-30 mg / kg every 4-6 hours to achieve phaseout the dose and interval input picked individually; trombasteniya Hlantsmana - a range of doses recommended for treatment of bleeding and prevention in patients who have to conduct surgery or invasive procedures is 90 micrograms (80 to 120 mcg) / kg body weight every 2 h (1,5-2,5 hrs), for maintaining hemostasis must enter at least 3 dose, bolus injections recommended as a slow infusion may be ineffective, treatment for trombasteniyi Hlantsmana patients in which phaseout resistance should first enter platelets. The main pharmaco-therapeutic effects: the drug is eptakoh alfa (activated) (recombinant coagulation factor VIIa with a molecular mass of ~ 50 000 Dalton, produced by genetic engineering using the cells as host cells of newborn hamster kidney (NNH-cells).; Mechanism the drug is to factor VIIa binding to tissue factor and this complex converts factors IX and X in the active form - IHa and Ha, which causes small amounts of prothrombin conversion to thrombin, in therapeutic doses, regardless of tissue factor directly activates factor X directly on the surface of activated platelets, which are exposed to harm it causes a lot of converting prothrombin to thrombin without the involvement of tissue factor, factor VIIa pharmacodynamic effect is to increase the local formation of factor Xa, thrombin and fibrin are theoretically not possible to completely eliminate the generalized activation of coagulation system in patients with diseases that contribute to the development of diffuse intravascular coagulation.
No comments:
Post a Comment